Table of Contents
ISRN Oncology
Volume 2012, Article ID 642106, 10 pages
http://dx.doi.org/10.5402/2012/642106
Review Article

Trends in Kaposi’s Sarcoma in Miami Beach from 1987 to 2007

1Department of Internal Medicine, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL 33140, USA
2Department of Hematology and Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
3Department of Public Health and Biostatistics, College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale-Davie, FL 33314, USA
4Department of Clinical Psychology, Nova Southeastern University, Fort Lauderdale-Davie, FL 33314, USA

Received 15 November 2012; Accepted 9 December 2012

Academic Editors: A. Berner and L. Hunakova

Copyright © 2012 Simon B. Zeichner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Kaposi, “Idiopathic multiple pigmented sarcoma of the skin,” CA: A Cancer Journal for Clinicians, vol. 32, pp. 342–347, 1982, English translation, Archiv für Dermatolgie und Syphilis, vol. 4, pp. 265–273, 1872. View at Publisher · View at Google Scholar
  2. P. S. Moore and Y. Chang, “Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection,” New England Journal of Medicine, vol. 332, no. 18, pp. 1181–1185, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Iscovich, P. Boffetta, R. Winkelmann, P. Brennan, and E. Azizi, “Classic Kaposi's sarcoma in Jews living in Israel, 1961–1989: a population-based incidence study,” Acquired Immune Deficiency Syndrome, vol. 12, no. 15, pp. 2067–2072, 1998. View at Google Scholar · View at Scopus
  4. E. Fenig, B. Brenner, E. Rakowsky, M. Lapidoth, A. Katz, and A. Sulkes, “Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel,” American Journal of Clinical Oncology, vol. 21, no. 5, pp. 498–500, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Cook-Mozaffari, R. Newton, V. Beral, and D. P. Burkitt, “The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic,” British Journal of Cancer, vol. 78, no. 11, pp. 1521–1528, 1998. View at Google Scholar · View at Scopus
  6. S. J. Olsen, Y. Chang, P. S. Moore, R. J. Biggar, and M. Melbye, “Increasing Kaposi's sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985,” Acquired Immune Deficiency Syndrome, vol. 12, no. 14, pp. 1921–1925, 1998. View at Google Scholar · View at Scopus
  7. V. Beral, T. A. Peterman, R. L. Berkelman, and H. W. Jaffe, “Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?” The Lancet, vol. 335, no. 8682, pp. 123–128, 1990. View at Google Scholar · View at Scopus
  8. J. N. Martin, D. E. Ganem, D. H. Osmond, K. A. Page-Shafer, D. Macrae, and D. H. Kedes, “Sexual transmission and the natural history of human herpesvirus 8 infection,” New England Journal of Medicine, vol. 338, no. 14, pp. 948–954, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Rezza, M. Andreoni, M. Dorrucci et al., “Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases,” Journal of the National Cancer Institute, vol. 91, no. 17, pp. 1468–1474, 1999. View at Google Scholar · View at Scopus
  10. F. Sitas, H. Carrara, V. Beral et al., “Antibodies against human herpesvirus 8 in black South African patients with cancer,” New England Journal of Medicine, vol. 340, no. 24, pp. 1863–1871, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. E. A. Engels, R. J. Biggar, V. A. Marshall et al., “Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma,” Acquired Immune Deficiency Syndrome, vol. 17, no. 12, pp. 1847–1851, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. E. E. Brown, D. Fallin, I. Ruczinski et al., “Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 5, pp. 926–934, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. J. Goedert, F. Vitale, C. Lauria et al., “Risk factors for classical Kaposi's sarcoma,” Journal of the National Cancer Institute, vol. 94, no. 22, pp. 1712–1718, 2002. View at Google Scholar · View at Scopus
  14. L. A. Anderson, C. Lauria, N. Romano et al., “Risk factors for classical Kaposi sarcoma in a population-based case-control study in sicily,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 12, pp. 3435–3443, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. R. Hoover, C. Black, L. P. Jacobson et al., “Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men,” American Journal of Epidemiology, vol. 138, no. 4, pp. 266–278, 1993. View at Google Scholar · View at Scopus
  16. B. Brenner, E. Rakowsky, A. Katz et al., “Tailoring treatment for Classical Kaposi's Sarcoma: comprehensive clinical guidelines,” International Journal of Oncology, vol. 14, no. 6, pp. 1097–1102, 1999. View at Google Scholar · View at Scopus
  17. S. Zurrida, C. Bartoli, F. Nole et al., “Classic Kaposi's sarcoma: a review of 90 cases,” Journal of Dermatology, vol. 19, no. 9, pp. 548–552, 1992. View at Google Scholar · View at Scopus
  18. G. Di Lorenzo, A. Kreuter, R. Di Trolio et al., “Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study,” Journal of Investigative Dermatology, vol. 128, no. 6, pp. 1578–1580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. AIDS in the United States, Department of Health and Human Serives Center for Disease Control and Prevention, Division of HIV/AIDS Prevention, Decemeber 2011, http://www.cdc.gov/hiv/resources/factsheets/geographic.htm.
  20. HIV/AIDS services, Miami-Dade Health Department, December 2011, http://www.dadehealth.org/hiv/HIVsurveillance.asp.
  21. “Surveillance Epidemiology and End Results,” National Cancer Institute, ICD conversion, Kaposi’s Sarcoma, 1975–2008, http://seer.cancer.gov/tools/conversion/.
  22. “Surveillance Epidemiology and End Results,” National Cancer Institute, Staging Variables, Kaposi’s Sarcoma, 1975–2008, http://seer.cancer.gov/seerstat/variables/seer/yr1973_2005/lrd_stage/.
  23. E. L. Kaplan and P. Meier, “Nonparametric estimation from incomplete observations,” Journal of the American Statistical Association, vol. 53, no. 282, pp. 457–481, 1958. View at Google Scholar
  24. D. R. Cox, “Regression models and life-tables,” Journal of the Royal Statistical Society, B, vol. 34, no. 2, pp. 187–220, 1972. View at Google Scholar
  25. D. W. Hosmer Jr. and S. Lemeshow, Applied Survival Analysis. Regression Modeling of Time to Event Data, John Wiley & Sons, New York, NY, USA, 1999.
  26. G. P. Suciu, S. Lemeshow, and M. Moeschberger, “Statistical test of equality of survival curves: reconsidering the options,” in Handbook of Statistics, N. Balakrishnan and C. R. Rao, Eds., vol. 23, chapter 13, pp. 251–262, Elsevier Science B.V., Amsterdam, The Netherlands, 2004. View at Google Scholar
  27. G. D. Datta, I. Kawachi, C. Delpierre, T. Lang, and P. Grosclaude, “Trends in Kaposi's sarcoma survival disparities in the United States: 1980 through 2004,” Cancer Epidemiology, Biomarkers & Prevention, vol. 19, no. 11, pp. 2718–2726, 2010. View at Publisher · View at Google Scholar
  28. B. Holkova, K. Takeshita, D. M. Cheng et al., “Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy,” Journal of Clinical Oncology, vol. 19, no. 18, pp. 3848–3851, 2001. View at Google Scholar · View at Scopus
  29. M. Borok, S. Fiorillo, I. Gudza et al., “Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related kaposi sarcoma in Zimbabwe,” Clinical Infectious Diseases, vol. 51, no. 3, pp. 342–349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. G. Sullivan, H. H. Hirsch, S. Franceschi et al., “Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study,” Acquired Immune Deficiency Syndrome, vol. 24, no. 14, pp. 2245–2252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Caterino-de-Araujo, M. C. Magri, and R. C. R. Manuel, “Patterns of antibodies against latent and lytic antigens of human herpesvirus 8 in an endemic population and patients with Kaposi's sarcoma in Mozambique,” Journal of Medical Virology, vol. 82, no. 9, pp. 1576–1581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Okroj, R. Tedeschi, R. Mancuso et al., “Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters,” Vaccine, vol. 29, no. 6, pp. 1129–1134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Guadalupe, B. H. Pollock, S. Westbrook et al., “Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 56, no. 1, pp. 83–90, 2011. View at Google Scholar
  34. E. Boffi El Amari, L. Toutous-Trellu, A. Gayet-Ageron et al., “Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era,” Acquired Immune Deficiency Syndrome, vol. 22, no. 9, pp. 1019–1028, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Brenner, E. Rakowsky, A. Katz et al., “Tailoring treatment for classical Kaposi's Sarcoma: comprehensive clinical guidelines,” International Journal of Oncology, vol. 14, no. 6, pp. 1097–1102, 1999. View at Google Scholar · View at Scopus
  36. S. Zurrida, C. Bartoli, F. Nole et al., “Classic Kaposi's sarcoma: a review of 90 cases,” Journal of Dermatology, vol. 19, no. 9, pp. 548–552, 1992. View at Google Scholar · View at Scopus
  37. F. Asiimwe, D. Moore, W. Were et al., “Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda,” Acquired Immune Deficiency Syndrome, vol. 25, no. 11, pp. 1395–1403, 2011. View at Publisher · View at Google Scholar
  38. K. M. Chu, G. Mahlangeni, S. Swannet, N. P. Ford, A. Boulle, and G. Van Cutsem, “AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa,” Journal of the International AIDS Society, vol. 13, no. 1, p. 23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. H. W. Jaffe, B. L. de Stavola, L. M. Carpenter, K. Porter, and D. R. Cox, “Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults,” Acquired Immune Deficiency Syndrome, vol. 25, no. 11, pp. 1395–1403, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Dogan, L. Dogan, F. Ozdemir et al., “Fifty-one Kaposi sarcoma patients,” Clinical and Translational Oncology, vol. 12, no. 9, pp. 629–633, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. L. Tornesello, B. Biryahwaho, R. Downing et al., “TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and caucasian patients,” Oncology, vol. 77, no. 5, pp. 328–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Katongole-Mbidde, L. Buonaguro, and F. M. Buonaguro, “Surveillance Epidemiology and End Results,” National Cancer Institute, Cancer Statistics, Kaposi’s Sarcoma, 1975–2008, http://seer.cancer.gov/csr/1975_2008/browse_csr.php?section=10&page=sect_10_table.01.html.
  43. “Surveillance Epidemiology and End Results,” National Cancer Institute, Cancer Statistics, Localized/Regional/Distant Stage Adjustments, 1975–2008, http://seer.cancer.gov/seerstat/variables/seer/yr1973_2005/lrd_stage/.
  44. L. Brambilla, V. Boneschi, M. Taglioni, and S. Ferrucci, “Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices,” European Journal of Dermatology, vol. 13, no. 1, pp. 83–86, 2003. View at Google Scholar · View at Scopus
  45. S. E. Krown, C. Metroka, and J. C. Wernz, “Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee,” Journal of Clinical Oncology, vol. 7, no. 9, pp. 1201–1207, 1989. View at Google Scholar · View at Scopus
  46. B. J. Dezube, L. Pantanowitz, and D. M. Aboulafia, “Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment,” AIDS Reader, vol. 14, no. 5, pp. 236–243, 2004. View at Google Scholar · View at Scopus
  47. C. M. Weintraub and R. B. Skudowitz, “Excision of 1 674 classic Kaposi's sarcomas,” South African Journal of Surgery, vol. 40, no. 2, p. 80, 2002. View at Google Scholar · View at Scopus
  48. D. Hauerstock, W. Gerstein, and T. Vuong, “Results of radiation therapy for treatment of classic Kaposi sarcoma,” Journal of Cutaneous Medicine and Surgery, vol. 13, no. 1, pp. 18–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. M. Kirova, E. Belembaogo, H. Frikha et al., “Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases,” Radiotherapy and Oncology, vol. 46, no. 1, pp. 19–22, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. J. W. Tappero, T. G. Berger, L. D. Kaplan, P. A. Volberding, and J. O. Kahn, “Cryotherapy for cutaneous Kaposi's Sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial,” Journal of Acquired Immune Deficiency Syndromes, vol. 4, no. 9, pp. 839–846, 1991. View at Google Scholar · View at Scopus
  51. J. H. von Roenn and M. Cianfrocca, “Treatment of Kaposi's sarcoma,” Cancer Treatment and Research, vol. 104, pp. 127–148, 2001. View at Google Scholar · View at Scopus
  52. G. F. Webster, “Local therapy for mucocutaneous Kaposi's sarcoma in patients with acquired immunodeficiency syndrome,” Dermatologic Surgery, vol. 21, no. 3, pp. 205–208, 1995. View at Google Scholar · View at Scopus
  53. L. Brambilla, V. Boneschi, G. Beretta, and A. F. Finzi, “Intralesional chemotherapy for Kaposi's sarcoma,” Dermatologica, vol. 169, no. 3, pp. 150–155, 1984. View at Google Scholar · View at Scopus
  54. R. B. Odom and D. K. Goette, “Treatment of cutaneous Kaposi's sarcoma with intralesional vincristine,” Archives of Dermatology, vol. 114, no. 11, pp. 1693–1694, 1978. View at Publisher · View at Google Scholar · View at Scopus
  55. G. S. Morganroth, “Topical 0.1% alitretinoin gel for classic Kaposi sarcoma,” Archives of Dermatology, vol. 138, no. 4, pp. 542–543, 2002. View at Google Scholar · View at Scopus
  56. N. E. Célestin Schartz, S. Chevret, C. Paz et al., “Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: a phase I to II, open-label trial in 17 patients,” Journal of the American Academy of Dermatology, vol. 58, no. 4, pp. 585–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Franceschi, L. D. Maso, M. Rickenbach et al., “Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy,” British Journal of Cancer, vol. 99, no. 5, pp. 800–804, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Grabar, B. Abraham, A. Mahamat, P. Del Giudice, E. Rosenthal, and D. Costagliola, “Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement,” Journal of Clinical Oncology, vol. 24, no. 21, pp. 3408–3414, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Mocroft, O. Kirk, N. Clumeck et al., “The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA study,” Cancer, vol. 100, no. 12, pp. 2644–2654, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Bower, M. Nelson, A. M. Young et al., “Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5224–5228, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. R. S. Leidner and D. M. Aboulafia, “Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome,” AIDS Patient Care and STDs, vol. 19, no. 10, pp. 635–644, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Di Lorenzo, A. Kreuter, R. Di Trolio et al., “Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study,” Journal of Investigative Dermatology, vol. 128, no. 6, pp. 1578–1580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. D. W. Northfelt, B. J. Dezube, J. A. Thommes et al., “Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial,” Journal of Clinical Oncology, vol. 16, no. 7, pp. 2445–2451, 1998. View at Google Scholar · View at Scopus
  64. S. Stewart, H. Jablonowski, F. D. Goebel et al., “Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 683–691, 1998. View at Google Scholar · View at Scopus
  65. P. S. Gill, J. Wernz, D. T. Scadden et al., “Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma,” Journal of Clinical Oncology, vol. 14, no. 8, pp. 2353–2364, 1996. View at Google Scholar · View at Scopus
  66. L. Martín-Carbonero, A. Barrios, P. Saballs et al., “Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma,” Acquired Immune Deficiency Syndrome, vol. 18, no. 12, pp. 1737–1740, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Welles, M. W. Seville, J. Lietzau et al., “Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma,” Journal of Clinical Oncology, vol. 16, no. 3, pp. 1112–1121, 1998. View at Google Scholar · View at Scopus
  68. P. S. Gill, A. Tulpule, B. M. Espina et al., “Paclitaxel is safe and effective in the treatment of advanced AIDS- related Kaposi's sarcoma,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1876–1883, 1999. View at Google Scholar · View at Scopus
  69. A. Tulpule, J. Groopman, M. W. Saville et al., “Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma,” Cancer, vol. 95, no. 1, pp. 147–154, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. F. C. Lee, K. Thornton, and B. Williams, “Low dose weekly paclitaxel is an effective first line treatment for patients with symptomatic AIDS-KS,” Proceedings of the American Society of Clinical Oncology, vol. 22, p. 825a, 2003. View at Google Scholar
  71. T. L. Soon, A. Tupule, B. M. Espina, and A. M. Levine, “Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma,” Cancer, vol. 103, no. 2, pp. 417–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. S. E. Krown, “AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa?” Cytokine and Growth Factor Reviews, vol. 18, no. 5-6, pp. 395–402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. C. S. Costa da Cunha, C. Lebbé, M. Rybojad et al., “Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b,” Archives of Dermatology, vol. 132, no. 3, pp. 285–290, 1996. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Bower, S. Collins, C. Cottrill et al., “British HIV association guidelines for HIV-associated malignancies 2008,” HIV Medicine, vol. 9, no. 6, pp. 336–388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Baker, “FDA approves 3TC and saquinavir. Food and drug administration,” Bulletin of Experimental Treatments for AIDS, pp. 5–9, 1995. View at Google Scholar · View at Scopus
  76. I. G. Williams and K. M. de Cock, “The XI international conference on AIDS. Vancouver 7–12 July 1996. A review of Clinical Science Track B,” Genitourinary Medicine, vol. 72, no. 5, pp. 365–369, 1996. View at Google Scholar